Jefferies: Semaglutide data is "reassuring"
Trial results for Novo Nordisk’s 50mg oral semaglutide are expected, according to investment bank Jefferies.
by marketwire, translated by christian radich hoffman
US-based investment bank Jefferies assesses that headline data from Novo Nordisk’s Oasis study with oral semaglutide in a 50mg dose was as expected.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk to submit obesity tablet for approval this year
For subscribers
Investor predicts huge Wegovy potential in US
For subscribers
